Preventive use of a hepatoprotectant against anti‐tuberculosis drug‐induced liver injury: A randomized controlled trial. Issue 2 (28th January 2016)

• Record Type: Journal Article
• Authors: Zhang, Simin; Pan, Hongqiu; Peng, Xianzhen; Lu, Hui; Fan, Hong; Zheng, Xianzhi; Xu, Guisheng; Wang, Min; Wang, Jianming
• Is Part Of: Journal of gastroenterology and hepatology. Volume 31:Issue 2(2016:Feb.)
• Page Start: 409
• Page End: 416
• Publication Date: 2016-01-28
• Subjects: clinical trial -- drug‐induced liver injury -- hepatoprotectant -- RCT -- tuberculosis; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.13070
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: Hepatoprotectants are routinely prescribed in China to prevent anti‐tuberculosis drug‐induced liver injury (ATLI). However, their biological mechanisms have not yet been clearly demonstrated. This study aims to evaluate the preventive effects of Silybum marianum against drug‐induced liver injury among tuberculosis patients and to provide clinical guidelines for tuberculosis management in China. Methods: A randomized controlled trial was performed in Jiangsu, China. Tuberculosis patients were randomly allocated to the experimental group (anti‐tuberculosis therapy plus S. marianum capsule) or the control group (anti‐tuberculosis therapy plus vitamin C tablet). The primary outcomes were the occurrence of probable and possible ATLI, the peak aspartate aminotransferase/alanine aminotransferase ratio and the maximum altered alkaline phosphatase or gamma‐glutamyl transferase. Results: The final analysis comprised 183 cases in the experiment group and 187 cases in the control group. The risk of developing probable ATLI was not significantly different between the two groups. During the follow‐up period, 43.72% of cases in the experiment group and 35.83% of cases in the control group were determined to have possible ATLI (relative risk = 1.23, 95% confidence interval: 0.94–1.54). When using a more strict definition of possible ATLI, the adjusted relative risk (95% confidence interval) was 1.76 (1.14–2.56). The risks of adverse drug reactions, prolonged treatment length, taking second‐line tuberculosis drugs, and the clearance of tuberculosis bacteria were similar between the two groups. Conclusions: No significant preventive effect of silymarin was found for either lowering the risk of liver injury or boosting the positive outcomes. Worse, we even found a potential risk of liver damage caused by the hepatoprotectant.